膀胱癌患者尿液血管内皮生长因子水平检测的临床意义

目的 探讨膀胱癌患者尿液血管内皮生长因子(VEGF)与肿瘤发生及浸润的关系.方法 应用酶联免疫吸附试验对48例膀胱癌患者(膀胱癌组)、45例健康体检者(对照组)尿液中VEGF水平进行检测.结果 膀胱癌组尿液VEGF水平(174.77±83.41)μg/L,明显高于对照组的(63.53±22.62)μg/L(P<0.01).其中浸润性膀胱癌患者尿液VEGF水平(223.00±83.13)μg/L,显著高于浅表性膀胱癌患者的(130.40±54.86)μg/L(P<0.01);膀胱癌G3级患者尿液VEGF水平(259.23±75.82)μg/L,显著高于G1级的(138.00±85.60)μg/L和G2级的(146.22±47.53)μg/L(P<0.01).结论 尿液VEGF水平与膀胱癌的临床分期及病理分级相关,可作为膀胱癌生物学行为的指标之一.

The clinical significance of urinary vascular endothelial growth factor measurement in patients with bladder cancer

Objective To investigate the relationship of urinary vascular endothelial growth factor (VEGF) and occurrence and invasiveness of bladder cancer. Method The expression of urinary VEGF in 48 patients with bladder cancer (bladder cancer group) and 45 normal cases (control group) were examined by ELISA immunohistochemical staining. Results VEGF levels in urine in bladder cancer group [(174.77±83.41) μg/L] were higher statistically than those in control group [(63.53 ±22.62) μg/L] (P < 0.01), and related to the staging and grading of tumors. VEGF levels were significant higher in invasive lesions [(223.00 ± 83.13) μg/L] than those in superficial ones [(130.40 ± 54.86) μg/L] (P < 0.01). VEGF levels of G3 [(259.23 ± 75.82) μg/L] were significant higher compared with G1 [(138.00± 85.60) μ g/L] and G2 [(146.22 ±47.53) μ g/L] (P < 0.01). Conclusion The concentration of urinary VEGF relates to the clinical staging and pathological grading, and it is a labeling index of the biological behavior of bladder cancer.